Powered By
Continue with Facebook
Continue with Email
If you’ve been diagnosed with hormone receptor-positive breast cancer, you might start treatment with hormonal therapy. Aromatase inhibitors, including letrozole (Femara) and anastrozole (Arimidex), are a common option for people who’ve gone through menopause.
Making treatment choices can feel overwhelming, especially because you’ll likely take this medication long term, but understanding your options can help. Breast cancer treatment should be a shared decision made between you and your breast cancer care team.
Continue reading to learn more about letrozole and anastrozole to make the best well-informed decision when working with your doctor.
Letrozole and anastrozole belong to a class of medications called aromatase inhibitors. These hormonal therapies are used to treat hormone receptor (HR)-positive breast cancer.
Most people take an aromatase inhibitor for five to 10 years. An aromatase inhibitor is often taken after breast cancer surgery and referred to as adjuvant treatment. If the drug is started before surgery, it’s known as neoadjuvant therapy.
Three aromatase inhibitors are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer: letrozole, anastrozole, and exemestane (Aromasin).
Aromatase inhibitors lower estrogen levels by blocking the production of this hormone in your body. Estrogen is made by aromatase, which is an enzyme (a type of protein that speeds up chemical reactions). Aromatase is found mostly in fat cells throughout your body.
Aromatase converts the hormone androgen into estrogen. Blocking aromatase causes estrogen levels to fall by about 95 percent, according to The University of Texas MD Anderson Cancer Center. Lower estrogen can help stop or slow the growth of cancer cells that are fueled by estrogen, such as HR-positive breast cancer.
Aromatase inhibitors can block estrogen production in your fat cells, but they can’t stop your ovaries from making estrogen. To be the most effective, aromatase inhibitors may be recommended after menopause, when the ovaries make less estrogen.
People who are premenopausal may sometimes be prescribed an aromatase inhibitor, but only when paired with ovarian function suppression (or ovarian removal). People who need hormonal therapy before menopause may take another medication, such as tamoxifen (Soltamox).
Clinical trials have found that aromatase inhibitors prevent breast cancer recurrence (return of the cancer) about 30 percent more effectively among postmenopausal women compared to drugs such as tamoxifen.
Therefore, after menopause, aromatase inhibitors are considered a first-line (preferred) hormone therapy for people with estrogen receptor-positive breast cancer.
Both letrozole and anastrozole come in tablets that you swallow whole with water. You can take either medication with or without food, but you should take it at the same time each day.
You should always take your medication exactly as your oncology team prescribes.
Clinical trials have found no significant difference in effectiveness between letrozole and anastrozole.
One of the most important studies comparing these two medications was the Femara Versus Anastrozole Clinical Evaluation (FACE) trial. This study included more than 4,000 postmenopausal women with HR-positive or node-positive early-stage breast cancer. Participants were randomized into two groups, with one group taking letrozole and the other taking anastrozole for five years or until breast cancer returned.
Researchers began the FACE study with a hypothesis (guess) that letrozole might work better than anastrozole. However, the results showed that letrozole didn’t lead to significantly better outcomes.
The researchers measured the study’s outcomes by determining how many participants survived at least five years without breast cancer returning — also known as disease-free survival (DFS). They also measured the overall survival rate, or the percentage of participants still alive after five years.
The five-year DFS rates were 84.9 percent for letrozole and 82.9 percent for anastrozole. Even though DFS was slightly higher for participants taking letrozole, the difference wasn’t statistically significant. The overall survival rate was also similar for both groups, with 89.9 percent for participants receiving letrozole and 89.2 percent for those taking anastrozole.
Like all drugs, even those sold over the counter, hormonal treatment for breast cancer comes with side effects. Many side effects of letrozole and anastrozole are similar. Both medications reduce the amount of estrogen in your body, resulting in adverse events (side effects) such as:
In addition, some aromatase inhibitors have been linked to side effects such as higher cholesterol, cardiovascular problems, and gastrointestinal issues.
Side effects may differ slightly between letrozole and anastrozole.
Key similarities and differences are summarized in this table.
The effectiveness and quality of life associated with the two primary aromatase inhibitors are similar.
The FACE study found no significant differences in the safety of letrozole and anastrozole. Both medications had about the same rate of side effects. However, not everyone reacts to medications the same way.
Differences in individuals and how each drug works may influence the likelihood of certain side effects. For example, letrozole has been shown to reduce estrogen more than anastrozole. This may lead to more side effects in some people.
Letrozole may be more likely to cause joint pain than anastrozole. In a 2020 study comparing almost 200 people taking either letrozole or anastrozole, more than half of all participants experienced joint pain. The researchers found that people on letrozole were significantly more likely to experience this side effect than those on anastrozole.
Joint pain can affect the tolerability of aromatase inhibitors. People taking letrozole were more likely to cut their treatment short due to joint pain.
This study also found that a higher body mass index (BMI) was associated with joint pain while taking an aromatase inhibitor. Many people report weight gain during breast cancer treatment, which may raise the risk of aching joints.
If you experience joint pain, talk to your doctor about the best ways to treat this symptom and how to manage your weight as a breast cancer survivor.
All aromatase inhibitors can cause osteoporosis, or weakened bones. People on aromatase inhibitors are usually closely monitored for bone density issues, and sometimes bone-protecting medicines are prescribed when appropriate.
Talk to your healthcare team about how you can prevent osteoporosis and bone fractures.
You’ll likely take letrozole or anastrozole for several years, so tolerability and the medication’s effect on your quality of life are important. The good news is that both medications are generally well tolerated.
Even though side effects are common, they won’t necessarily reduce your overall quality of life. A 2011 study in the United Kingdom aimed to find out how the same people would tolerate letrozole versus anastrozole.
Using a crossover study design, the researchers gave about 180 people each drug for 12 weeks. The findings showed that neither letrozole nor anastrozole had a negative effect on quality of life.
About 31 percent of participants said they liked letrozole better, and about 36 percent preferred anastrozole. The remainder had no preference.
Choosing the right treatment should be a shared conversation with your doctor. Tell your care team about your goals and concerns, and ask your oncologist about the possible benefits and risks.
If you’re worried about a particular side effect, discuss ways it may be prevented or managed if it develops. By participating fully in the decision, you’ll feel more confident about your treatment plan.
On MyBCTeam, people share their experiences with breast cancer, get advice, and find support from others who understand.
Is letrozole or anastrozole part of your treatment plan for hormone receptor-positive breast cancer? Let others know in the comments below.
Get updates directly to your inbox.
I have put 4 kgs on since starting anastrozole only 4 weeks ago, is this likely to continue. Would I be eligible to start mounjaro and would
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
Just over a year on letrozole and have experienced many of the symptoms occasionally but only joint pain regularly. I can manage the occasional symptoms with careful attention to my diet. I have lost… read more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.